We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
18
9 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Active, not recruiting
7
38.9%
Completed
2
11.1%
Not yet recruiting
Recruiting
No approval data available
- BioNTech's BNT327, a VEGF x PD-L1 bispecific antibody, demonstrates encouraging Phase II survival data in triple-negative breast cancer (TNBC). - The bispecific antibody, combined with nab-paclitaxel, achieved a 13.5-month progression-free survival (PFS) as a first-line treatment for advanced TNBC. - These findings suggest a potential advantage over standard PD-1 blockers, positioning BNT327 as a promising therapeutic option for TNBC. - BioNTech is preparing to advance BNT327 to Phase III trials based on the positive Phase II results presented at the San Antonio Breast Cancer Symposium.
